Q-linea Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Q-linea wird ein jährliches Gewinn- und Umsatzwachstum von 38% bzw. 50.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 64.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -125.8% betragen.

Wichtige Informationen

38.0%

Wachstumsrate der Gewinne

64.5%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	25.5%
Wachstumsrate der Einnahmen	50.5%
Zukünftige Eigenkapitalrendite	-125.8%
Analystenabdeckung	Low
Zuletzt aktualisiert	04 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

OM:QLINEA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	136	-90	-75	-60	1
12/31/2025	162	-153	-77	-64	2
12/31/2024	26	-178	-152	-142	1
3/31/2024	8	-224	-212	-204	N/A
12/31/2023	6	-229	-237	-229	N/A
9/30/2023	6	-239	-268	-260	N/A
6/30/2023	5	-249	-269	-259	N/A
3/31/2023	8	-257	-288	-273	N/A
12/31/2022	14	-269	-268	-251	N/A
9/30/2022	18	-256	-276	-256	N/A
6/30/2022	16	-246	-288	-266	N/A
3/31/2022	16	-241	-260	-243	N/A
12/31/2021	10	-231	-261	-249	N/A
9/30/2021	6	-237	-248	-241	N/A
6/30/2021	5	-236	-231	-225	N/A
3/31/2021	1	-226	-242	-234	N/A
12/31/2020	1	-219	-251	-237	N/A
9/30/2020	0	-224	-228	-213	N/A
6/30/2020	0	-210	-218	-202	N/A
3/31/2020	1	-197	-201	-188	N/A
12/31/2019	1	-177	-177	-170	N/A
9/30/2019	1	-155	-160	-155	N/A
6/30/2019	2	-149	-153	-151	N/A
3/31/2019	1	-141	-140	-138	N/A
12/31/2018	1	-128	-124	-123	N/A
9/30/2018	2	-111	-108	-106	N/A
6/30/2018	2	-97	-90	-89	N/A
12/31/2017	2	-68	N/A	-63	N/A
12/31/2016	0	-60	N/A	-53	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: QLINEA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: QLINEA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: QLINEA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: QLINEADie Einnahmen des Unternehmens (50.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (1.8% pro Jahr).

Hohe Wachstumseinnahmen: QLINEADie Einnahmen des Unternehmens (50.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: QLINEA wird voraussichtlich in 3 Jahren unrentabel sein.

Q-linea Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 49%

Consensus revenue estimates increase by 24%, EPS downgraded

No longer forecast to breakeven

Forecast to breakeven in 2026

Consensus revenue estimates decrease by 27%

Price target decreased by 13% to kr10.00

Recent updates

Consensus revenue estimates increase by 49%

First quarter 2024 earnings released: kr0.48 loss per share (vs kr2.10 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates increase by 24%, EPS downgraded

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings: EPS and revenues miss analyst expectations

Q-Linea AB Appoints Anders Ljunggren as Managing Director, Effective 1 March 2024

Q-linea AB (publ) Announces CEO Changes

Q-linea AB (publ) to Report First Half, 2024 Results on Jul 11, 2024

Q-linea AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024

Here's Why Q-linea (STO:QLINEA) Must Use Its Cash Wisely

Forecast to breakeven in 2026

Consensus revenue estimates decrease by 27%

Price target decreased by 13% to kr10.00

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Q-Linea AB (Publ) Announces Jonas Jarvius to Step Down as CEO Before Summer 2024

Q-linea AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 262.885275 million.

New major risk - Share price stability

Consensus revenue estimates decrease by 40%, EPS upgraded

Q-linea AB (publ) Completes its 510(k) Application for US Market Approval

Second quarter 2023 earnings released: kr2.23 loss per share (vs kr2.53 loss in 2Q 2022)

Q-linea AB (publ) Announces First Patient Enrolls in Lifetimes

Consensus revenue estimates increase by 40%, EPS downgraded

Insufficient new directors

Full year 2022 earnings: EPS and revenues miss analyst expectations

CFO & Investor Relations Officer recently bought kr143k worth of stock

Full year 2022 earnings released: kr9.20 loss per share (vs kr8.19 loss in FY 2021)

Q-linea AB (publ) Announces CFO Changes, Effective May 1, 2023

Q-linea AB (publ) Prepare to Start Additional Testing for US 510(K) Application

Q-Linea Participates in Comparative Rapid AST Study

VP & Research Director recently bought kr241k worth of stock

Consensus revenue estimates fall by 21%

Q-linea AB (publ) to Report Q1, 2023 Results on May 04, 2023

Third quarter 2022 earnings released: kr2.03 loss per share (vs kr1.68 loss in 3Q 2021)

Consensus revenue estimates fall by 34%

Second quarter 2022 earnings released: kr2.53 loss per share (vs kr2.47 loss in 2Q 2021)

Consensus revenue estimates fall by 82%

Will Q-linea (STO:QLINEA) Spend Its Cash Wisely?

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Price target decreased to kr165

Q-linea AB (publ) Announces Marcus Storch Not Available for Re-Election as Member of Board of Directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

CEO & President recently bought kr480k worth of stock

Insufficient new directors

Now 22% undervalued after recent price drop

Price target decreased to kr165

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS and revenues miss analyst expectations

Q-linea (STO:QLINEA) Is In A Good Position To Deliver On Growth Plans

Forecast to breakeven in 2023

Third quarter 2021 earnings released: kr1.68 loss per share (vs kr1.80 loss in 3Q 2020)

Forecast to breakeven in 2023

Second quarter 2021 earnings released: kr2.47 loss per share (vs kr2.37 loss in 2Q 2020)

CEO & President recently sold kr14m worth of stock

Q-linea AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 301.4 million.

Q-linea AB (publ) Initiates US 510(k) Clinical Study for ASTar

Consensus forecasts updated

First quarter 2021 earnings released: kr2.34 loss per share (vs kr2.44 loss in 1Q 2020)

Full year 2020 earnings released: kr8.64 loss per share (vs kr7.74 loss in FY 2019)

Price target increased to kr185

Q-linea AB (publ) Receives First Order on ASTar

Full year 2020 earnings released: kr8.64 loss per share (vs kr7.74 loss in FY 2019)

Revenue beats expectations

We're Hopeful That Q-linea (STO:QLINEA) Will Use Its Cash Wisely

New 90-day low: kr150

Do Institutions Own Q-linea AB (publ) (STO:QLINEA) Shares?

Q-linea AB Initiates Pivotal Clinical Study for ASTar in Europe